Q1 Earnings Estimate for VNDA Issued By HC Wainwright

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Stock analysts at HC Wainwright issued their Q1 2027 earnings estimates for Vanda Pharmaceuticals in a research report issued on Monday, March 2nd. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will post earnings of ($0.28) per share for the quarter. HC Wainwright has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.07) EPS and Q4 2027 earnings at ($0.03) EPS.

A number of other equities research analysts have also recently commented on VNDA. Jefferies Financial Group raised their price objective on shares of Vanda Pharmaceuticals from $5.00 to $7.50 and gave the stock a “hold” rating in a research note on Wednesday, December 31st. Zacks Research lowered shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, December 17th. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 5th. Finally, Wall Street Zen lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Vanda Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $14.13.

Vanda Pharmaceuticals Stock Up 4.6%

Vanda Pharmaceuticals stock opened at $8.20 on Wednesday. The business’s 50-day moving average price is $7.56 and its 200 day moving average price is $5.97. The company has a quick ratio of 2.38, a current ratio of 2.39 and a debt-to-equity ratio of 0.01. The firm has a market cap of $484.70 million, a price-to-earnings ratio of -2.20 and a beta of 0.55. Vanda Pharmaceuticals has a 52 week low of $3.81 and a 52 week high of $9.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing the consensus estimate of ($2.18) by ($0.21). The company had revenue of $57.22 million for the quarter, compared to analyst estimates of $59.28 million. Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Torren Management LLC acquired a new position in shares of Vanda Pharmaceuticals in the 4th quarter valued at $25,000. Russell Investments Group Ltd. increased its stake in shares of Vanda Pharmaceuticals by 456.6% in the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 5,328 shares during the last quarter. CWM LLC increased its position in shares of Vanda Pharmaceuticals by 424.6% in the 2nd quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 7,575 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its stake in Vanda Pharmaceuticals by 3,010.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 10,389 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 10,055 shares in the last quarter. Finally, Jain Global LLC bought a new position in Vanda Pharmaceuticals during the fourth quarter worth $94,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Insider Transactions at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos sold 156,235 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $8.17, for a total value of $1,276,439.95. Following the transaction, the chief executive officer owned 2,704,496 shares in the company, valued at $22,095,732.32. This trade represents a 5.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CMO Joakim Wijkstrom sold 30,800 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total value of $254,716.00. Following the completion of the sale, the chief marketing officer directly owned 333,469 shares in the company, valued at $2,757,788.63. This represents a 8.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 314,342 shares of company stock worth $2,583,985 in the last three months. 10.00% of the stock is owned by corporate insiders.

Key Vanda Pharmaceuticals News

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: FDA grants a formal evidentiary public hearing for Vanda’s sNDA for HETLIOZ (tasimelteon) in jet lag disorder — described as a landmark action and the first drug approval hearing in over 40 years. This raises the chance for public review and could materially affect approval timing and outcome. PR Newswire
• Positive Sentiment: HC Wainwright maintains a Buy view with a $24 price target and issued updated quarterly EPS forecasts for FY2027 (Q1–Q4 estimates provided). The firm’s constructive outlook and high price target support upside sentiment despite near-term losses. MarketBeat VNDA
• Neutral Sentiment: Technical/volume and valuation context — the stock is trading above its 50-day and 200-day moving averages, market cap is roughly $485M and the company remains loss-making (negative P/E). Current intraday volume is below the 3-month average, which may mute short-term moves. MarketBeat VNDA
• Negative Sentiment: Significant insider selling: CEO Mihael Polymeropoulos, CFO Kevin Moran, CMO Joakim Wijkstrom and two SVPs (Gunther Birznieks and Timothy Williams) each sold large blocks on March 2 (each sale ~30k–156k shares, representing single-digit percentage reductions in their holdings). Multiple high-level executive sales can be perceived negatively by investors and may pressure sentiment even if sales are for diversification or tax reasons. Relevant SEC filings: CEO (Read More.), CFO (Read More.), CMO (Read More.), SVP Gunther Birznieks (Read More.), SVP Timothy Williams (Read More.).

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.